Saturday 17 October 2026
Export PEN’s income statement to Excel — free account
Penumbra, Inc.
PEN Healthcare Medical Devices
Penumbra, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 17.5% from fiscal 2024. In the quarter to June 2026, revenue grew 14.9%, EPS fell 24.8%, free cash flow grew 10.8% and total debt fell 9.90%, each against the same quarter a year earlier. Revenue growth for ten consecutive years, operating cash flow growth for three.
320.86
0.34
−0.11%
Follow PEN
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
132.03 | 710.86 | 643.16 | 117.34 | 0.00 | 1,915.47 | 0.00 | 104.16 | 641.84 | 68.03 |
Piotroski F-Score |
3 | 6 | 7 | 5 | 2 | 6 | 1 | 8 | 5 | 8 |
Altman Z-Score |
29.68 | 25.96 | 28.72 | 20.85 | 21.62 | 23.00 | 14.79 | 16.91 | 15.88 | 20.17 |
P/S ratio |
7.41 | 8.93 | 9.38 | 10.43 | 11.17 | 14.13 | 9.88 | 8.88 | 7.68 | 8.62 |
P/FCF ratio |
0.00 | 18,739.39 | 217.22 | 1,256.55 | 0.00 | 0.00 | 0.00 | 115.85 | 62.29 | 69.17 |
Altman Z″-Score (non-manufacturers) |
11.51 | 10.09 | 9.23 | 7.25 | 7.54 | 6.47 | 5.88 | 7.10 | 6.72 | 8.59 |
Beneish M-Score |
(1.29) | (1.90) | (2.45) | (1.93) | (2.35) | (1.80) | (1.91) | (2.47) | (3.11) | (2.48) |
P/Operating CF |
(188.40) | (3,285.07) | 553.93 | 1,197.50 | (3,004.91) | (1,139.49) | 6,260.77 | 259.22 | 179.52 | 139.91 |
P/B ratio |
7.32 | 7.44 | 9.88 | 11.76 | 9.81 | 11.07 | 8.38 | 7.97 | 7.97 | 8.48 |
Price to Tangible BV |
7.32 | 8.09 | 10.77 | 12.61 | 10.12 | 15.16 | 11.14 | 9.98 | 9.38 | 9.64 |
EV/Sales |
6.92 | 8.28 | 8.92 | 10.13 | 10.74 | 13.82 | 9.69 | 8.63 | 7.41 | 8.25 |
EV/EBITDA |
937.52 | 559.03 | 746.95 | 99.72 | 0.00 | 1,160.29 | 269.96 | 90.61 | 268.53 | 56.00 |
EV/Operating CF |
(142.31) | 217.87 | 137.84 | 208.08 | (181.14) | 1,087.63 | (147.45) | 93.84 | 52.57 | 48.50 |
EV/FCF |
(68.93) | 17,389.76 | 206.76 | 1,220.75 | (103.82) | (884.97) | (109.49) | 112.58 | 60.13 | 66.17 |
Quick Ratio |
4.81 | 5.28 | 4.28 | 3.24 | 3.58 | 3.16 | 2.70 | 3.25 | 3.21 | 4.01 |
Current Ratio |
7.37 | 7.41 | 6.22 | 5.09 | 5.83 | 5.53 | 5.21 | 6.06 | 6.01 | 6.64 |
Net Debt/EBITDA |
(66.23) | (43.39) | (37.79) | (2.92) | 10.10 | (25.64) | (5.37) | (2.63) | (9.65) | (2.54) |
Debt/Assets |
0.00% | 0.00% | 0.00% | 4.02% | 3.29% | 2.13% | 1.81% | 1.52% | 1.42% | 1.13% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.06 | 0.04 | 0.03 | 0.02 | 0.02 | 0.02 | 0.01 |
Asset Turnover |
0.92 | 0.85 | 0.90 | 0.93 | 0.75 | 0.72 | 0.65 | 0.72 | 0.77 | 0.84 |
Operating CF/Net income |
(0.86) | 2.73 | 4.36 | 0.55 | 2.12 | 1.80 | 27.80 | 1.07 | 12.02 | 1.34 |
Capex/Depreciation |
(4.14) | (3.98) | (1.56) | (2.73) | (1.61) | (1.29) | (0.79) | (0.59) | (0.89) | (3.65) |
| 5.94% | 1.40% | 1.60% | 10.67% | (2.80%) | 0.66% | (0.21%) | 8.35% | 1.20% | 13.78% | |
| 5.18% | 1.19% | 1.33% | 8.21% | (2.11%) | 0.51% | (0.15%) | 6.21% | 0.91% | 10.58% | |
ROIC |
(0.61%) | 0.39% | (0.24%) | 9.19% | (6.08%) | (0.65%) | 0.45% | 5.03% | 0.70% | 13.09% |
Return on Tangible Assets |
5.94% | 1.29% | 1.74% | 11.43% | (2.80%) | 0.86% | (0.30%) | 10.87% | 1.64% | 15.44% |
Average Days of Receivables |
60.07 | 63.44 | 67.18 | 70.61 | 74.64 | 65.39 | 87.63 | 69.57 | 51.23 | 49.41 |
Research and Development Expense of Revenue |
9.07% | 9.49% | 8.13% | 9.45% | 16.07% | 13.99% | 9.37% | 7.98% | 7.93% | 6.40% |
Selling, General and Administrative Expense of Revenue |
56.32% | 55.22% | 50.88% | 49.82% | 51.22% | 50.61% | 53.09% | 47.85% | 48.05% | 47.26% |
Intangible Assets out of Total Assets |
0.00 | 0.07 | 0.07 | 0.05 | 0.02 | 0.21 | 0.18 | 0.15 | 0.11 | 0.09 |
Share Based Compensation of Revenue |
5.56% | 5.34% | 4.14% | 3.92% | 4.56% | 8.80% | 4.41% | 4.77% | 3.86% | 4.22% |
Graham Net Nets |
0.11 | 0.10 | 0.08 | 0.05 | 0.07 | 0.04 | 0.05 | 0.06 | 0.06 | 0.07 |
Graham Number |
9.77 | 5.89 | 7.27 | 20.98 | 0.00 | 9.36 | 0.00 | 40.29 | 15.75 | 61.42 |
Earnings Yield |
0.76% | 0.14% | 0.16% | 0.85% | (0.25%) | 0.05% | (0.03%) | 0.96% | 0.16% | 1.47% |
Free Cash Flow Yield |
(1.36%) | 0.01% | 0.46% | 0.08% | (0.93%) | (0.11%) | (0.90%) | 0.86% | 1.61% | 1.45% |
Revenue per Share |
8.64 | 10.12 | 13.03 | 15.75 | 15.67 | 20.33 | 22.39 | 27.57 | 30.92 | 36.07 |
Operating CF per Share |
(0.42) | 0.38 | 0.84 | 0.77 | (0.93) | 0.26 | (1.47) | 2.53 | 4.36 | 6.13 |
Capex per Share |
(0.45) | (0.46) | (0.28) | (0.64) | (0.69) | (0.58) | (0.51) | (0.42) | (0.55) | (1.64) |
Free Cash Flow per Share |
(0.87) | (0.07) | 0.56 | 0.13 | (1.62) | (0.32) | (1.98) | 2.11 | 3.81 | 4.49 |
Cash per Share |
4.23 | 6.51 | 5.88 | 5.45 | 7.40 | 6.93 | 4.97 | 7.53 | 8.80 | 14.00 |
Shareholders Equity per Share |
8.75 | 12.14 | 12.37 | 13.97 | 17.83 | 25.95 | 26.40 | 30.70 | 29.79 | 36.68 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
8.75 | 12.14 | 12.37 | 13.97 | 17.83 | 25.95 | 26.40 | 30.70 | 29.79 | 36.68 |
Free Cash Flow |
(26.44) | (2.34) | 19.21 | 4.54 | (58.00) | (11.68) | (74.96) | 81.13 | 147.30 | 174.93 |
Working Capital |
228.03 | 330.65 | 344.66 | 372.09 | 511.77 | 558.28 | 610.77 | 764.26 | 792.78 | 1,033.55 |
Capital Expenditures |
(13.63) | (15.03) | (9.60) | (22.11) | (24.76) | (21.18) | (19.30) | (16.20) | (21.18) | (63.73) |
Net Current Asset Value |
222.12 | 305.98 | 318.14 | 282.85 | 432.51 | 391.15 | 383.67 | 538.04 | 568.88 | 817.77 |
EV/EBIT |
0.00 | 2,373.37 | 0.00 | 116.74 | 0.00 | 0.00 | 1,349.47 | 124.18 | 954.45 | 61.17 |
Capex to Sales |
0.05 | 0.05 | 0.02 | 0.04 | 0.04 | 0.03 | 0.02 | 0.02 | 0.02 | 0.05 |
Price to Operating Income |
0.00 | 2,557.56 | 0.00 | 120.16 | 0.00 | 0.00 | 1,376.30 | 127.79 | 988.76 | 63.94 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.15 | 0.12 | 0.17 | 0.16 | 0.32 | 0.28 | 0.37 | 0.38 | 0.38 | 0.15 |
Cash ROIC |
(6.69%) | (0.38%) | 3.08% | 0.65% | (6.24%) | (0.95%) | (6.19%) | 5.44% | 9.74% | 8.78% |
Accounts Receivable Turnover |
7.24 | 6.59 | 6.36 | 5.83 | 5.08 | 6.02 | 5.02 | 5.23 | 6.47 | 7.85 |
Accounts Payable Turnover |
27.70 | 21.46 | 20.41 | 15.07 | 15.21 | 19.78 | 15.56 | 13.96 | 15.03 | 13.96 |
Inventory Turnover |
1.43 | 1.39 | 1.45 | 1.31 | 1.19 | 1.13 | 1.04 | 1.04 | 1.11 | 1.10 |
Average Days of Payables |
16.22 | 21.15 | 19.58 | 31.44 | 23.17 | 18.00 | 31.22 | 26.37 | 26.01 | 27.49 |
Days of Inventory on Hand |
288.14 | 297.02 | 277.19 | 318.30 | 360.55 | 353.33 | 390.84 | 376.79 | 337.70 | 341.51 |
Average Receivables |
36.39 | 50.67 | 69.95 | 93.90 | 110.25 | 124.27 | 168.66 | 202.58 | 184.72 | 178.84 |
Average Payables |
3.34 | 5.43 | 7.47 | 11.64 | 14.61 | 13.77 | 20.05 | 26.92 | 29.24 | 33.03 |
Average Inventory |
64.89 | 83.96 | 105.32 | 134.37 | 186.26 | 241.52 | 298.76 | 361.01 | 397.38 | 419.14 |
Average Assets |
286.05 | 392.46 | 495.84 | 590.45 | 744.44 | 1,033.62 | 1,307.57 | 1,463.60 | 1,544.74 | 1,679.85 |
Average Common Equity |
249.53 | 333.48 | 411.41 | 454.01 | 561.70 | 795.86 | 976.39 | 1,088.90 | 1,164.94 | 1,289.27 |
Columns are period end dates